Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > September 23, 2020
Daily News
September 23, 2020
- Keytruda’s 1st Line Gastric Cancer Submission Pulled in Japan
September 23, 2020
- 42 Nippon Chemiphar Reps to Hit Exit under Voluntary Redundancy
September 23, 2020
- Sanofi’s Dupixent Adds Pen Formulation in Japan
September 23, 2020
- Japan’s COVAX Participation Meant to Confirm Importance of Global Access to Vaccines: Minister
September 23, 2020
- MHLW Grants Orphan Status to 5 APIs
September 23, 2020
- Lucentis Biosimilar Filed in Japan; Senju/Gene Techno Eye 2021 Approval
September 23, 2020
- HPV Vaccine Advocate Junko Mihara Picked as Vice MHLW Chief
September 23, 2020
- New Cabinet Well Organized, Full of People with Practical Experience: JPMA Director General
September 23, 2020
- Drug Wholesalers’ Sales Up 2.54%, Improving Profit Rates in FY2019: JPWA
September 23, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…